Menu
Dr. Jason McKeown is a UK-trained medical doctor with a PhD in Noninvasive Neurostimulation. Through his work in the field of neuroscience and interest in advanced technology, he believes there is a better way to treat diseases affecting the lives of people worldwide. His dedication to advancing medical technology, combined with his deep understanding of diabetes, anxiety, and insomnia, has positioned him as a trailblazer in the field.
In 2016, as a visiting scholar at the University of California Center for Brain & Cognition, Dr. McKeown researched neuroscience and neuromodulation in partnership with Professor V.S. Ramachandran. It was in this lab that the technology behind the Modius products was born. After years of research and development, Dr. McKeown led the Neurovalens team through a successful study into the effectiveness of the Modius Sleep device on the treatment of chronic insomnia, resulting in Medical Device Regulatory Approval from the U.S. FDA in October 2023. In March 2024, Neurovalens also received FDA approval for Modius Stress, a treatment for anxiety.
In April 2024, Dr. McKeown was appointed visiting scholar at the University of California, San Diego (UCSD), in the Department of Psychiatry. Dr. McKeown is an active member of the General Medical Council with the National Health Service in the UK, the Society for Neuroscience with UCSD, and an associate member of the Royal College of Emergency Medicine, the Association of British Neurologists, and the Royal College of Physicians with UCSD.
Kate Willis is a leader in the healthcare and MedTech industries, known for her strategic prowess and innovative approaches. Currently, she serves as the Vice President of Commercialization at Neurovalens, responsible for leading all global and U.S. commercial functions, including U.S. product launches. Her career highlights include serving as the Director of Government Affairs and Advocacy, where she shaped industry standards and policies. Prior to joining Neurovalens, Kate served as an executive leader in premier companies such as Nevro, Medtronic, Nuvasive, and Zimmer Biomet, where her initiatives spurred organizational growth.
Beyond her healthcare expertise, Kate is a recognized figure in the arts as a producer and investor, with successful ventures in Broadway, West End, and film productions. Her unique flair for bridging the realms of business and entertainment underlines her diverse capabilities and visionary outlook. Committed to making a difference in the community, Kate is an active board member of Lighthouse Youth & Family Services and the Children’s Law Center in Cincinnati, where she dedicates her time and resources to improving the lives of others.
Keep up to date with our latest products, research and company news.
Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.
Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.
